Treating Cancer by Disrupting Energy and Building Block Needs
Madera is the leader in highly potent and specific activators of the mitochondrial protease, ClpP. Together with our academic collaborators and the NIH/NCI, we have established the in vitro and in vivo performance of these agents. Notably, our agents provide a new mechanism of action that is effective on a number of drug resistant cancer cells and patient-derived tissue samples. This technology is backed by the broadest patent portfolio in the area.
Contact our company for additional details about our research and development efforts.
Our mission is to identify and develop cancer therapeutics that treat cancer by disrupting a tumor and its environment’s unique energy requirements.